O’Melveny Worldwide

Portia Ku is the managing partner of O’Melveny’s Shanghai office and a leader within the firm’s China practice. Through her 25-year career in M&A and capital markets, Portia has earned a position as a top advisor to companies, their executives, boards, and investors for guiding on their most important corporate and transactional matters. Her accomplishments are numerous, and span groundbreaking IPOs and other capital markets matters, innovative and complex mergers and acquisitions, and venture capital and private equity financings. Portia’s versatility encompasses not just her many key areas of practice, but industry specialties as well, which include technology, life sciences, health care, electric vehicles, batteries, green energy packaging, and other green energy products. All told, Portia has advised on approximately US$20 billion in M&A and capital markets matters.

Year in and year out, Portia has successfully completed a variety of deals throughout both favorable and challenging market conditions. She applies her expansive technical experience, strategic execution, and solutions-oriented mindset to guide clients through highly complicated transactions.

Public and Private Offerings (Companies):

  • eHi Car Services in its US$325 million Regulation S high-yield bond offering due 2027
  • Belite Bio, Inc (NASDAQ: BLTE) in its US$30 million follow-on offering
  • Belite Bio, Inc (NASDAQ: BLTE) in its US$36 million IPO and listing on NASDAQ
  • Pharmaron in a Regulation S private offering of US$600 million of zero coupon convertible bonds due 2026
  • Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
  • eHi Car Services (NYSE: EHIC) in its US$120 million IPO and listing on the NYSE
  • Montage Technology Group Limited (NASDAQ: MONT) in its US$81.7 million IPO and listing on NASDAQ
  • China Kanghui Holdings (NYSE: KH) in its US$78.7 million IPO and listing on the NYSE
  • iSoftStone Holdings Ltd. (NYSE: ISS) in its US$162 million IPO and listing on the NYSE
  • 7 Days Group Holdings (NYSE: SVN) in its US$127.8 million IPO and listing on the NYSE
  • Giant Interactive Group Inc. (NYSE: GA) in its US$1.02 billion IPO and listing on the NYSE
  • WuXi PharmaTech (NYSE: WX) in its US$212 million IPO and listing on the NYSE
  • Acorn International, Inc. (NYSE: ATV) in its US$119.4 million IPO and listing on the NYSE
  • Mindray Medical International Limited (NYSE: MR) in its US$320 million IPO and listing on the NYSE
  • Christine International Holdings Ltd. (1210.HK) in its HK$400 million IPO and listing on the Hong Kong Stock Exchange
  • LifeTech Scientific Corporation (8122.HK) in its HK$283 million IPO on the Growth Enterprise Market of the Hong Kong Stock Exchange
  • Besunyen Holdings Company Limited (0926.HK) in its HK$1.3 billion IPO and listing on the Hong Kong Stock Exchange

Mergers and Acquisitions:

  • Dragonfly Energy Corp., an energy provider and battery producer, in its definitive business combination with a Nasdaq-listed SPAC company, which will make it a public company valued at US$500 million
  • Pharmaron in its US$118.7 million acquisition of Allergan Biologics Limited from AbbVie, Inc.
  • Pharmaron in its US$137.5 million acquisition of US-based Absorption Systems
  • Sundia Meditech Group in its US$80 million sale to a consortium led by Advent International Corporation
  • Pharmaron in its US$30 million seed round investment in AccuGen Group
  • BlueFocus/Blue Impact in the definitive share exchange agreement to be acquired by a SPAC listed on the NYSE
  • the three founders of Nanjing USA, Inc. in their trade sale to Roo Hsing Co., Ltd., a Taiwan listed company
  • eHi Car Services Co., Ltd. (NYSE: EHIC) in its US$937.5 million management buyout transaction
  • the two founders of Adicon Holdings Limited in a sale of 66% of the company to a consortium comprised of the Chinese-listed company Meinian Onehealth Healthcare, funds managed by the Caryle Group, and four Carlyle co-investors
  • Vivo Capital, in the consortium’s US$505 million acquisition of Angiotech Pharmaceuticals, Inc., a company specializing in the design and manufacturing of high performance surgical knives and wound closure products
  • Pharmaron, in its definitive agreement to acquire a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc. (SNBL CPC)
  • Pharmaron, in its definitive agreement with a consortium led by CITIC M&A Fund and Legend Capital, which will invest more than US$280 million in the company
  • Giant Interactive Group Inc. (NYSE: GA) in US$3 billion going private transaction
  • Xitogen Technologies in its sale to Danaher Corporation (NYSE: DHR)
  • China Hydroelectric Corporation (NYSE: CHC) in US$190 million buyout by controlling shareholder
  • China Kanghui in its US$816 million acquisition by Medtronic
  • LifeTech in a series of strategic investment transactions with Medtronic, including the sale of HK$2.18 billion of convertible notes to Medtronic
  • a shareholder group of China Hydroelectic Corporation in a cross-border proxy contest to remove a majority of the members of CHC’s board of directors and replace them with directors nominated by the shareholder group. The proxy contest culminated in the shareholder group’s proposals passing on all counts, followed by CHC and its management agreeing to settle on terms favorable to the shareholder group

Public and Private Offerings (Underwriters):

  • Credit Suisse and Deutsche Bank in US$174 million US IPO of Tudou Holding Ltd. (NASDAQ: TUDO)
  • Morgan Stanley and CICC in US$132 million US IPO of Concord Medical Services Holdings (NYSE: CCM)
  • Credit Suisse and Citigroup in US$73 million US IPO of Chemspec International Limited (NYSE: CPC)
  • Merrill Lynch in US$108 million US IPO of China Sunergy Co., Ltd. (NASDAQ: CSUN)
  • the underwriters in the IPO of CNOOC
  • the underwriters in the IPO of Comtech
  • the underwriters in the IPO of TravelSky Technology
  • the underwriters in the IPO of Sohu.com

Business and Commercial Litigation:

  • JHL Biotech in achieving a favorable settlement over a biosimilars related trade secrets claim made by Genentech


  • Mandarin Chinese
  • Taiwanese


Bar Admissions

  • California
  • New York
  • Taiwan


  • Yale University, LL.M.
  • National Taiwan University, LL.B.

Honors & Awards

  • Recognized as a “Leading Lawyer” (2017) and “Highly Regarded” (2018-2023) in Capital Markets and Private Equity by IFLR1000
  • Recognized by Daily Journal as a “Top Women Lawyer”